TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose S-ketamine in Women With Prenatal Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Maternal age ≥18 years;~2. Prenatal Edinburgh postnatal depression scale score ≥10 points.~Exclusion Criteria:~1. A clear history of mental illness (depression, schizophrenia, etc.) or communication difficulties;~2. Severe pregnancy complications, such as severe preeclampsia, placental implantation, HELLP (syndrome hemolytic anemia, elevated liver function and low platelet count) syndrom, placenta previa, and placental abruption;~3. American Society of Anesthesiologists classification ≥III;~4. Presence of contraindications to ketamine/s-ketamine use, such as refractory hypertension, severe cardiovascular disease (New York Heart Association classification ≥III), and hyperthyroidism.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S-katamine group (Type: EXPERIMENTAL): For women in this group, study drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.
- Placebo group (Type: PLACEBO_COMPARATOR): For women in this group, study drug (20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. Women will be monitored for 60 minutes and then sent back to the ward.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oropharyngeal Administration of Colostrum to Extremely Low Gestational Age Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* premature infant with a gestational age less than 28 weeks born at Seoul National University Hospital and admit to the Seoul National University Children's Hospital NICU immediately after birth~* parents of the infant signed to the informed consent form with voluntary agreement~Exclusion Criteria:~* infants with major congenital anomalies or chromosomal syndromes~* infants of mothers not willing to provide colostrum in the first week of life~* infants of mothers with known infectious diseases that may be transmitted through the breast milk such as HIV, hepatitis C or active TB

- Gender: ALL
- Minimum Age: 48 Hours
- Maximum Age: 96 Hours
- Healthy Volunteers: t

Study Arms:
- Colostrum (Type: EXPERIMENTAL): oropharyngeal administration of own mother's colostrum
- Placebo (Type: PLACEBO_COMPARATOR): oropharyngeal administration of sterile water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Diagnosis of cancer No symptomatic brain metastases~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No cardiac pacemaker Other: No clinical evidence of current or impending bowel obstruction Able to understand English~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent interferon Chemotherapy: No prior chemotherapy Concurrent cisplatin or doxorubicin based chemotherapy required No multiple day doses of cisplatin, doxorubicin, hexamethylmelamine, dacarbazine, nitrosourea or streptozocin Other concurrent chemotherapy allowed on 1 or multiple days Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy Surgery: Not specified Other: Serotonin receptor antagonist antiemetic (ondansetron, granisetron, tropisetron, or dolasetron mesylate) required

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed multiple myeloma Stage II disease Symptomatic due to progressive disease OR Stage III disease No stage I multiple myeloma or smoldering myeloma~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: More than 4 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3\* Platelet count at least 100,000/mm3\* \*Unless due to multiple myeloma Hepatic: Bilirubin no greater than 2.0 mg/dL ALT and AST no greater than 3 times upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN Renal: Elevated creatinine allowed Cardiovascular: LVEF at least 50% by MUGA or ECHO No active angina No myocardial infarction within the past 6 months Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception at least 4 weeks prior to, during, and for at least 4 weeks after study No grade II or greater pre-existing neuropathy No other concurrent or prior active malignancy within the past 2 years except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix Prior T1a or T1b prostate cancer (detected incidentally at transurethral resection of prostate (TURP) and comprising less than 5% of resected tissue) allowed if PSA normal since TURP HIV negative No AIDS-related illness No other medical condition that would preclude study~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy for multiple myeloma Endocrine therapy: No more than 1 course of prior pulse dexamethasone Prior steroids of less than 1 month duration for emergent indications or life-threatening lesions (e.g., hypercalcemia or spinal cord compromise) allowed Radiotherapy: Prior radiotherapy allowed Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Myocardial Ischemia and Transfusion Pilot

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 18 or older;~* STEMI (ST segment elevated myocardial infarction)~* NSTEMI (Non ST segment elevation myocardial infarction)~* unstable angina~* stable coronary artery disease (undergoing cardiac catheterization during the index hospitalization);~* written informed consent has been obtained~* hemoglobin concentration less than 10 g/dL at the time of random allocation.~Exclusion Criteria:~* bleeding cannot be controlled at the cardiac catheterization puncture site and/or require surgery to repair vessel~* retroperitoneal bleeding requiring surgery~* clinically important hemodynamic instability based on the judgment of the treating physician~* terminal malignancy or life expectancy less than 6 months~* scheduled for cardiac surgery within the next 30 days~* symptomatic at the time of randomization~* declines blood transfusion~* history of a clinically significant transfusion reaction~* inability to provide informed consent;~* enrolled in a competing study~* previous participation in the MINT trial~* any patient who in the judgment of the research team should not be enrolled in the trial. This would include, but not be limited to, factors such alcohol or drug dependence, or psychiatric illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liberal Transfusion Strategy (Type: EXPERIMENTAL): Patients randomly allocated to the liberal transfusion strategy receive one unit of packed red cells following randomization and receive enough blood to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days. Any transfusion following the initial unit of packed red cells must be preceded by blood test documenting a hemoglobin concentration below 10 g/dL.
- Restrictive transfusion strategy (Type: EXPERIMENTAL): Receive a transfusion if they develop symptoms related to anemia. Transfusion is also permitted, but not required, in the absence of symptoms only if the hemoglobin concentration falls below 8 g/dL. Blood is administered one unit at a time and the presence of symptoms is reassessed. Only enough blood is given to relieve symptoms. If the transfusion is given because the hemoglobin concentration falls below 8 g/dL, then only enough blood is given to increase the hemoglobin concentration above 8 g/dL.~Symptoms of anemia that will be indications for transfusion are: 1) Definite angina requiring treatment with sublingual nitroglycerin or equivalent therapy. 2) Unexplained tachycardia or hypotension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent must be obtained before any study assessment is performed.~* Males and females of non-childbearing potential and of legal age (at least 18 years or older as defined by local law).~* Asian patients with mild to moderate essential hypertension, untreated or currently taking antihypertensive therapy with up to two drugs.~Key Exclusion Criteria:~* Women of child-bearing potential.~* History of angioedema, drug-related or otherwise~* History of hypersensitivity to LCZ696, valsartan, or drugs of similar chemical classes.~* Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥ 180 mmHg) at screening or at the end of the washout period.~* History or evidence of a secondary form of hypertension,~* Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke.~* History of myocardial infarction, coronary bypass surgery or percutaneous coronary intervention (PCI) during 12 month prior to screening.~* Current or history of hypertensive retinopathy.~* Previous or current diagnosis of heart failure (NYHA Class II-IV).~* Clinically significant valvular heart disease at screening.~Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 followed by Valsartan (Type: EXPERIMENTAL): Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks
- Valsartan followed by LCZ696 (Type: EXPERIMENTAL): Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Nicotine Dependence and Acute Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age at least 18 at the beginning of the study~* Smoking at least 10 cigarettes a day (1/2 pack)~* Meets DSM-IV criteria for major depressive episode~Exclusion Criteria:~* Currently pregnant~* Currently breastfeeding~* Currently diagnosed with a seizure disorder, liver disease, kidney disease, congestive heart failure or diabetes mellitis~* History of a seizure, seizure disorder, significant head trauma or central nervous system tumor~* Family history of seizures~* Currently using intravenous drugs~* Currently using any drugs (marijuana, alcohol, cocaine, opiates, stimulants, etc.) on a daily basis~* Currently using any over-the-counter stimulants and anorectics (diet pills)~* Currently on fluoxetine (Prozac), bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL) or any other antidepressants, monoamine oxidase inhibitors, antipsychotics, benzodiazepines, theophylline, systemic steroids or levodopa~* Currently on NRT or bupropion (Zyban)~* Current or past diagnosis of anorexia nervosa~* Previous allergic response to fluoxetine, bupropion, or NRT~* Previous failed quit attempt using NRT and bupropion in combination~* Current suicidal ideation~* Current or past psychosis, mania/hypomania, or any other Axis I or Axis II psychiatric diagnosis other than major depression and nicotine dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bupropion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent.~* Male and aged 18 years and over.~* Diagnosed with PE according to DMS-IV criteria and ISSM definition~* Diagnosed with lifelong PE~* Acceptable response to Baseline PEP~* Subject must be in a stable heterosexual and monogamous relationship and the partner must provide consent~* Acceptable sexual encounters in the Baseline period.~Exclusion Criteria:~* Subject, or his sexual partner, has received an investigational (non-registered) drug within 30 days of Screening.~* Subject has erectile dysfunction~* The subject, or his sexual partner, has a physical or psychological condition that would prevent them from undertaking the study procedures, including, but not limited to, the following:~  * Urological disease~ * Ongoing significant psychiatric disorder not controlled by medication.~* Subject has safety testing abnormalities at the Screening Visit~* Subjects taking excluded medications or receiving any treatment for PE~* Subject, or his sexual partner, has a current history of alcohol or drug abuse,~* The subject, or his sexual partner, is unlikely to understand or be able to comply with study procedures, for whatever reasons.~* Subject, or his sexual partner, has known drug sensitivity to amide-type local anesthetics.~* Subjects with pregnant partners~* Subject with sexual partners of child-bearing potential and not using appropriate contraception~* Subject, or his sexual partner, has a history of Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency or use of medications that would increase susceptibility to methemoglobinemia (e.g. anti-malarial agents).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Blind Active (Type: ACTIVE_COMPARATOR): Double-blind Phase: Subjects will be randomised to PSD502 respectively if the patient meets all the entry criteria.
- Double-Blind Placebo (Type: PLACEBO_COMPARATOR): Double-blind Phase: Subjects will be randomised to Placebo respectively if the patient meets all the entry criteria.
- Open Label Phase (Type: ACTIVE_COMPARATOR): Subjects will all receive PSD502 if they wish to continue in the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Active subfoveal choroidal neovascular (CNV) lesion or juxtafoveal lesion secondary to age-related macular AMD~* An ETDRS BCVA score between 60 and 25 (inclusive) letters~Exclusion Criteria:~* Previous treatment for wet AMD or previous treatment for CNV due to other causes in the Study Eye~* Clinically significant ocular disorders which may interfere with assessment of visual acuity, assessment of toxicity, or fundus photography in the Study Eye~* Poorly controlled diabetes mellitus (defined as HbA1c\>7%)~* Any clinically significant cardiovascular, renal or hepatic conditions, recent surgery, or malignancy, that would make the participant unsuitable for the study

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.5 mg ranibizumab with 2.0 mg OPT-302 (Type: EXPERIMENTAL): 0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
- 0.5 mg ranibizumab with 0.5 mg OPT-302 (Type: EXPERIMENTAL): 0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
- 0.5 mg ranibizumab with sham (Type: SHAM_COMPARATOR): 0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Acute ischemic stroke that can be randomized within 48 hours of symptoms onset~* neurological deficit: 4 ≤ NIHSS ≤ 10~* CT or MRI scan ruling out hemorrhage or other pathology~* the first onset of ischemic stroke or previous stroke with no obvious sequelae (mRS≤1)~* Signed informed consent by patient self or legally authorized representatives~Exclusion Criteria:~* intracranial hemorrhage and hemorrhagic cerebral infarction~* Thrombolysis for ischemic stroke~* Allergy to clopidogrel and/or aspirin~* History of stroke with serious sequelae~* Severe systemic disease (such as severe infection, severe hepatic and renal dysfunction)~* Clear indication for anticoagulation (atrial fibrillation, mechanical cardiac valves, deep venous thrombosis, pulmonary embolism)~* History of intracranial hemorrhage~* Planned treatment with nonsteroidal anti-inflammatory drugs to affect platelet function~* Anticoagulation within 10 days~* Gastrointestinal bleed or major surgery within 3 months~* Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months~* Planned surgery or intervention to stop antiplatelet therapy~* Ischemic stroke induced by angiography or surgery~* Pregnancy or childbirth within the previous 4 weeks~* Patients who have been treated with any other investigational drug within 3 months of enrollment~* Severe noncardiovascular comorbidity with life expectancy \<3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clopidogrel plus aspirin group (Type: EXPERIMENTAL): the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
- aspirin group (Type: EXPERIMENTAL): the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be between the ages of 18 and 60;~* Have dx of opioid dependence according to DSM-IV criteria~* be in good general health as determined by complete physical and laboratory tests;~* Under some form of criminal justice supervision for at least 12 months;~* Have a negative result for urinary opioids and no sign of opiate withdrawal after IV (or IM) injection of 0.8 mg of naloxone; and~* Express a goal of opiate free treatment rather than agonist maintenance~Exclusion Criteria:~* Current drug or alcohol dependence that requires medical supervision;~* untreated psychiatric disorders that might make participation hazardous (e.g. untreated psychosis, bipolar disorder with mania, significant suicide risk). Adequately treated psychiatric disorders and appropriate psychotropic medications would be allowed.~  3. Active medical illness that might make participation hazardous (e.g., untreated hypertension, hepatitis with AST or ALT \>3 times upper limit of normal, unstable diabetes or heart disease). Adequately treated medical conditions are acceptable; 4. female subjects who are pregnant or lactating, or female subjects of childbearing potential who are not using birth control (oral contraceptives, barrier (diaphragm or condom) plus spermicide, or levonorgestriel implant); 5. Liver failure or liver function test levels greater than three times normal; 6. History of allergic reaction to naltrexone; 7. History of a drug overdose in the past 3 years; and 8. Current diagnosis of chronic pain disorder for which opioids are prescribed for pain relief.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Depot Naltrexone (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete